IL147367A0 - Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists, process for their preparation and pharmaceutical compositions comprising them - Google Patents

Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists, process for their preparation and pharmaceutical compositions comprising them

Info

Publication number
IL147367A0
IL147367A0 IL14736797A IL14736797A IL147367A0 IL 147367 A0 IL147367 A0 IL 147367A0 IL 14736797 A IL14736797 A IL 14736797A IL 14736797 A IL14736797 A IL 14736797A IL 147367 A0 IL147367 A0 IL 147367A0
Authority
IL
Israel
Prior art keywords
pyrrolidinyl
preparation
pharmaceutical compositions
kappa agonists
ethylamine compounds
Prior art date
Application number
IL14736797A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL147367A0 publication Critical patent/IL147367A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Mechanical Coupling Of Light Guides (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL14736797A 1996-09-18 1997-08-21 Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists, process for their preparation and pharmaceutical compositions comprising them IL147367A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IBPCT/IB96/00957 1996-09-18
IL12895997A IL128959A0 (en) 1996-09-18 1997-08-21 Pyrrolidinyl and pyrrolinyl enthylamine compounds as kappa agonists
PCT/IB1997/001021 WO1998012177A1 (en) 1996-09-18 1997-08-21 Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists

Publications (1)

Publication Number Publication Date
IL147367A0 true IL147367A0 (en) 2002-08-14

Family

ID=11004480

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14736897A IL147368A0 (en) 1996-09-18 1997-08-21 Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists, process for their preparation and pharmaceutical compositions comprising them
IL14736797A IL147367A0 (en) 1996-09-18 1997-08-21 Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists, process for their preparation and pharmaceutical compositions comprising them
IL12895997A IL128959A0 (en) 1996-09-18 1997-08-21 Pyrrolidinyl and pyrrolinyl enthylamine compounds as kappa agonists

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL14736897A IL147368A0 (en) 1996-09-18 1997-08-21 Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists, process for their preparation and pharmaceutical compositions comprising them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL12895997A IL128959A0 (en) 1996-09-18 1997-08-21 Pyrrolidinyl and pyrrolinyl enthylamine compounds as kappa agonists

Country Status (38)

Country Link
US (7) US6201007B1 (xx)
EP (1) EP0934264B1 (xx)
JP (2) JP3195368B2 (xx)
KR (1) KR100339666B1 (xx)
CN (1) CN1237962A (xx)
AP (1) AP1016A (xx)
AR (1) AR008168A1 (xx)
AT (1) ATE249433T1 (xx)
AU (1) AU719895B2 (xx)
BG (1) BG64194B1 (xx)
BR (1) BR9711506A (xx)
CA (1) CA2266006C (xx)
CO (1) CO4920224A1 (xx)
DE (1) DE69724805T2 (xx)
DK (1) DK0934264T3 (xx)
DZ (1) DZ2309A1 (xx)
EA (1) EA001341B1 (xx)
ES (1) ES2205248T3 (xx)
HR (1) HRP970509A2 (xx)
ID (1) ID19611A (xx)
IL (3) IL147368A0 (xx)
IS (1) IS4992A (xx)
MA (1) MA26441A1 (xx)
NO (1) NO313550B1 (xx)
NZ (1) NZ334439A (xx)
OA (1) OA10996A (xx)
PA (1) PA8437201A1 (xx)
PE (1) PE109998A1 (xx)
PL (1) PL332546A1 (xx)
PT (1) PT934264E (xx)
SK (1) SK32799A3 (xx)
TN (2) TNSN97092A1 (xx)
TR (1) TR199900590T2 (xx)
TW (1) TW432047B (xx)
UA (1) UA60310C2 (xx)
WO (1) WO1998012177A1 (xx)
YU (1) YU13899A (xx)
ZA (1) ZA978358B (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999051587A1 (fr) 1998-04-01 1999-10-14 Ono Pharmaceutical Co., Ltd. Derives de thiophene condenses et medicaments contenant ceux-ci comme principe actif
EP0982297A3 (en) * 1998-08-24 2001-08-01 Pfizer Products Inc. Process for the preparation of hydroxy-pyrrolidinyl hydroxamic acid derivatives being opioid kappa receptor agonists
AU2002247886A1 (en) * 2001-04-30 2002-11-11 Pfizer Products Inc. Process for preparing hydroxypyrrolidinyl ethylamine compounds useful as kappa agonists
WO2003072544A1 (en) * 2002-02-28 2003-09-04 Pfizer Products Inc. Crystalline anhydrous and monohydrate benzoate salts of (2's,3s)-3-hydroxy-n-{2{n-methyl-n-4-(n-propylamino-carbonyl)phenyl]amino-2-phenyl}-ethylpyrrolidine
AU2003269399A1 (en) * 2002-11-01 2004-05-25 Pfizer Products Inc. Process for the preparation of pyrrolidinyl ethylamine compounds via a copper-mediated aryl amination
CN1972914A (zh) * 2004-03-31 2007-05-30 詹森药业有限公司 作为组胺h3受体配合体的非咪唑杂环化合物
US7746514B2 (en) * 2004-04-14 2010-06-29 Hung-Yi Hsu Scanner and exposure control method thereof
US20070213319A1 (en) * 2006-01-11 2007-09-13 Angion Biomedica Corporation Modulators of hepatocyte growth factor/c-Met activity
CA2653940C (en) 2006-05-30 2015-07-14 Janssen Pharmaceutica N.V. Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
CN101511807A (zh) * 2006-06-29 2009-08-19 詹森药业有限公司 组胺h3受体的取代的苯甲酰胺调节剂
CN105712977B (zh) 2007-11-20 2021-06-29 詹森药业有限公司 作为组胺h3受体调节剂的环烷基氧基吡啶化合物和杂环烷基氧基吡啶化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8801304D0 (en) 1988-01-21 1988-02-17 Ici Plc Diamine compounds
DE4034785A1 (de) * 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
DE3935371A1 (de) 1988-12-23 1990-07-05 Merck Patent Gmbh Stickstoffhaltige ringverbindungen
US5232978A (en) * 1988-12-23 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung 1-(2-arylethyl)-pyrrolidines
WO1994018165A1 (en) 1993-02-12 1994-08-18 Pfizer Inc. Sulfonamide compounds as opioid k-receptor agonists
IL117440A0 (en) * 1995-03-31 1996-07-23 Pfizer Pyrrolidinyl hydroxamic acid compounds and their production process

Also Published As

Publication number Publication date
AU3781297A (en) 1998-04-14
PT934264E (pt) 2004-01-30
PE109998A1 (es) 1999-01-13
DK0934264T3 (da) 2004-01-26
JP2001316344A (ja) 2001-11-13
EA001341B1 (ru) 2001-02-26
IS4992A (is) 1999-03-05
AP9701082A0 (en) 1997-10-31
EP0934264B1 (en) 2003-09-10
ZA978358B (en) 1999-03-17
US20010009921A1 (en) 2001-07-26
HRP970509A2 (en) 1998-08-31
AR008168A1 (es) 1999-12-09
DE69724805D1 (de) 2003-10-16
AU719895B2 (en) 2000-05-18
US20010011091A1 (en) 2001-08-02
ES2205248T3 (es) 2004-05-01
CO4920224A1 (es) 2000-05-29
US20010014683A1 (en) 2001-08-16
OA10996A (en) 2001-11-06
JP3195368B2 (ja) 2001-08-06
DZ2309A1 (fr) 2002-12-28
NO313550B1 (no) 2002-10-21
EP0934264A1 (en) 1999-08-11
PL332546A1 (en) 1999-09-13
NO991294D0 (no) 1999-03-17
UA60310C2 (uk) 2003-10-15
DE69724805T2 (de) 2004-07-01
US6303602B1 (en) 2001-10-16
EA199900209A1 (ru) 1999-10-28
US6313302B2 (en) 2001-11-06
US6201007B1 (en) 2001-03-13
WO1998012177A1 (en) 1998-03-26
TW432047B (en) 2001-05-01
US6307061B2 (en) 2001-10-23
ATE249433T1 (de) 2003-09-15
BG103239A (en) 1999-09-30
CA2266006C (en) 2003-11-04
US20010020024A1 (en) 2001-09-06
US6294569B2 (en) 2001-09-25
CA2266006A1 (en) 1998-03-26
MA26441A1 (fr) 2004-12-20
SK32799A3 (en) 2000-09-12
BR9711506A (pt) 1999-08-24
TR199900590T2 (xx) 1999-07-21
TNSN97156A1 (fr) 2005-03-15
IL147368A0 (en) 2002-08-14
AP1016A (en) 2001-10-08
ID19611A (id) 1998-07-23
BG64194B1 (bg) 2004-04-30
JP2000516634A (ja) 2000-12-12
US20010008890A1 (en) 2001-07-19
PA8437201A1 (es) 1999-12-27
CN1237962A (zh) 1999-12-08
YU13899A (sh) 2000-03-21
TNSN97092A1 (ar) 1999-12-31
US6310061B2 (en) 2001-10-30
KR20000036225A (ko) 2000-06-26
NZ334439A (en) 2000-09-29
US6294557B1 (en) 2001-09-25
KR100339666B1 (ko) 2002-06-05
IL128959A0 (en) 2000-02-17
NO991294L (no) 1999-03-17

Similar Documents

Publication Publication Date Title
HUP0103333A3 (en) Pyrroloindoles, pyridoindoles and azepinoindiles as 5-ht2c agonists, process for their preparation and pharmaceutical compositions containing them
HUP9700358A3 (en) New oxazolidinon derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0004024A3 (en) Azabenzimidazole-based compounds, process for their preparation and pharmaceutical composition thereof
HUP0004040A3 (en) Pleuromutilin derivatives as antimicrobials, process for their preparation, pharmaceutical compositions, comprising thereof and their use
HUP0100431A3 (en) Adamantana derivatives, pharmaceutical compositions comprising them and process for preparing them
HU227841B1 (en) 2-phenyl substituted imidazotriazinones, process for their preparation and pharmaceutical compositions thereof
IL127798A (en) N-substituted indol-3-glyoxylamides, process for their preparation and pharmaceutical compositions comprising them
HUP0600527A2 (en) Substituted triazolo-pyridazine derivatives as ligands for gaba receptors, process for their preparation and pharmaceutical compositions containing them
HUP0201343A3 (en) Hypolipidemic benzothiazepine compounds, process for their preparation and pharmaceutical compositions containing them
HUP9802422A3 (en) Substituted isoquinoline-3-carboxamide derivatives, process for producing them and pharmaceutical compositions containing them
IL135920A0 (en) 2-aryl -8-oxodihydropurine derivative, process for the preparation thereof, pharmaceutical composition containing the same and intermediate therefor
HUP0000426A3 (en) Novel benzonaphthyridines, pharmaceutical compositions and use thereof and process for their preparation
HUP0001555A3 (en) Tetrahydro-imidazo-naphthyridine derivatives, pharmaceutical compositions thereof and process for their preparation
HUP0102512A3 (en) Bridged indenopyrrolocarbazoles, process for their preparation, pharmaceutical compositions containing them and their use
HUP0102215A3 (en) Benzoylpyridazines, pharmaceutical compositions containing the same and process for their preparation
HK1039122A1 (zh) 取代的6-苄基-4-氧代嘧啶，其製備方法以及含該化合物的藥物組合物
HUP9802757A3 (en) New naphthalene compounds, a process for their preparation and pharmaceutical compositions containing them
EG23982A (en) Synthetic polysaccharides, process for their preparation and pharmaceutical compositions containing them
IL147368A0 (en) Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists, process for their preparation and pharmaceutical compositions comprising them
HUP0002724A3 (en) Clasto-lactacystin betha-lactone, analogs and intermediates thereof, process for their preparation and pharmaceutical compositions containing them
HUP9801089A3 (en) Benzenesulfonamide derivatives, process for their preparation, pharmaceutical compositions containing them
HUT77375A (hu) Enterokinetikus hatású benzamidszármazékok, az ezeket tartalmazó gyógyszerkészítmények és eljárás a vegyületek előállítására
HUP0103347A3 (en) Aminoalcohol derivatives and their use as betha 3 adrenergic agonists, process for their preparation and pharmaceutical compositions containing them
HUP9902784A3 (en) Indan-1-ol compounds, process for their preparation and pharmaceutical compositions containing them
HUP0104202A3 (en) Thiazole-derivatives, process for their preparation and pharmaceutical compositions containing them